Pre-order Enquiry
Request Free Sample
Global Automated Insulin Delivery Device Market Research Report 2021
SKU ID : QYR-19363015 | Publishing Date : 14-Oct-2021 | No. of pages : 118
The Automated Insulin Delivery Device is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
Most Automated Insulin Delivery Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an Automated Insulin Delivery System is referred to as a "closed-loop" system, an "Artificial pancreas" system, or an "autonomous system for glycemic control."
An Automated Insulin Delivery System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
The global Automated Insulin Delivery Device market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Automated Insulin Delivery Device volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Automated Insulin Delivery Device market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Automated Insulin Delivery Device Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
Other Systems
Segment by Application
Hospital
Clinic
Medical Research Center
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Medtronic
Dexcom
Abbott
Insulet
Tandem Diabetes Care
Bigfoot Biomedical
Beta Bionics
Admetsys
Defymed
Micro Tech Medical
Most Automated Insulin Delivery Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an Automated Insulin Delivery System is referred to as a "closed-loop" system, an "Artificial pancreas" system, or an "autonomous system for glycemic control."
An Automated Insulin Delivery System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
The global Automated Insulin Delivery Device market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Automated Insulin Delivery Device volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Automated Insulin Delivery Device market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Automated Insulin Delivery Device Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
Other Systems
Segment by Application
Hospital
Clinic
Medical Research Center
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Medtronic
Dexcom
Abbott
Insulet
Tandem Diabetes Care
Bigfoot Biomedical
Beta Bionics
Admetsys
Defymed
Micro Tech Medical
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
